Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome (opens original article in a new tab)

Teva submitted a New Drug Application for ecopipam, a potential first-in-class treatment for pediatric Tourette syndrome, supported by positive Phase 3 trial results.

• Teva submitted an NDA for ecopipam, a first-in-class therapy for pediatric Tourette syndrome.
• Phase 3 trials showed ecopipam significantly delayed relapse in patients compared to placebo.
• Ecopipam received FDA Orphan Drug and Fast Track designations.